- US-listed companies
- Finch Therapeutics Group, Inc.
- Income statement
Finch Therapeutics Group, Inc. (FNCHQ) Income statement
Market cap
$11.88M
P/E ratio
| 2021/12 | 2022/12 | 2023/12 | |
| Revenue | 19 | 1 | 0 |
| Revenue growth (%) | - | ||
| Research & development | 57 | 58 | 7 |
| Operating margin (%) | |||
| Operating expenses | 79 | 116 | 84 |
| Operating income | -60 | -116 | -84 |
| Income before tax | -58 | -115 | -78 |
| Pretax margin (%) | -313.8 | -13,315.4 | -73,098.1 |
| Provision for income taxes | - | - | -3 |
| Effective tax rate (%) | - | - | |
| Net income | -58 | -115 | -75 |
| Net income margin (%) | |||
| Earnings per share | - | -2.4 | -46.59 |
| Diluted EPS | - | -2.4 | -46.59 |
| EBITDA | |||
| EBITDA margin (%) |